Rezvilutamide

瑞维鲁胺

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameRezvilutamide
Drug Alias Name艾瑞恩ArianeSHR-3680
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAndrogen Receptor antagonists
TargetsAndrogen Receptor
Therapy Area/IndicationsHormone-Sensitive Prostate NeoplasmsHormone-Resistant Prostate NeoplasmsHepatic Insufficiency +[8] 
Global Approved IndicationsProstatic Neoplasms
Approved Indications in ChinaProstatic Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2022/06/29
Country/TerritoryCzechiaBulgariaPoland +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesFudan UniversityShanghai Hengrui Pharmaceutical Co LtdJiangsu Hengrui Medicine Co Ltd
Inactive CompaniesAtridia Pty Ltd
Active IndicationsHormone-Sensitive Prostate NeoplasmsHepatic InsufficiencyProstatic Neoplasms +[5] 
Inactive IndicationsHormone-Resistant Prostate NeoplasmsProstatic Neoplasms, Castration-ResistantNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia